Enhancing temozolomide antiglioma response by inhibiting O6-methylguanine-DNA methyltransferase with selected phytochemicals: in silico and in vitro approach
Abstract The aim of our study was to investigate the potential of rutin, catechin, dehydrozingerone, naringenin, and quercetin, both alone and in combination with temozolomide, to inhibit the expression of O6-methylguanine-DNA methyltransferase (MGMT) in glioma cells. MGMT has been shown to be a major cause of temozolomide resistance in glioma. Our study used both in silico and in vitro methods to assess the inhibitory activity of these phytochemicals on MGMT, with the goal of identifying the most effective combination of compounds for reducing temozolomide resistance. After conducting an initial in silico screening of natural compounds against MGMT protein, five phytochemicals were chosen based on their high docking scores and favorable binding energies. From the molecular docking and simulation studies, we found that quercetin showed a good inhibitory effect of MGMT with its high binding affinity. C6 glioma cells showed increased cytotoxicity when treated with the temozolomide and quercetin combination. It was understood from the isobologram and combination index plot that the drug combination showed a synergistic effect at the lowest dose. Quercetin when combined with temozolomide significantly decreased the MGMT levels in C6 cells in comparison with the other drugs as estimated by ELISA. The percentage of apoptotic cells increased significantly in the temozolomide–quercetin group indicating the potency of quercetin in decreasing the resistance of temozolomide as confirmed by acridine orange/ethidium bromide staining. Our experiment hence suggests that temozolomide resistance can be reduced by combining the drug with quercetin which will serve as an effective therapeutic target for glioblastoma treatment..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
3 Biotech - 13(2023), 12 vom: 02. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vibhavari, R. J. A. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
-methylguanine-DNA methyltransferase |
|---|
| Anmerkungen: |
© King Abdulaziz City for Science and Technology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s13205-023-03821-7 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053612914 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053612914 | ||
| 003 | DE-627 | ||
| 005 | 20231209064638.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231103s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13205-023-03821-7 |2 doi | |
| 035 | |a (DE-627)SPR053612914 | ||
| 035 | |a (SPR)s13205-023-03821-7-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vibhavari, R. J. A. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Enhancing temozolomide antiglioma response by inhibiting O6-methylguanine-DNA methyltransferase with selected phytochemicals: in silico and in vitro approach |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © King Abdulaziz City for Science and Technology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a Abstract The aim of our study was to investigate the potential of rutin, catechin, dehydrozingerone, naringenin, and quercetin, both alone and in combination with temozolomide, to inhibit the expression of O6-methylguanine-DNA methyltransferase (MGMT) in glioma cells. MGMT has been shown to be a major cause of temozolomide resistance in glioma. Our study used both in silico and in vitro methods to assess the inhibitory activity of these phytochemicals on MGMT, with the goal of identifying the most effective combination of compounds for reducing temozolomide resistance. After conducting an initial in silico screening of natural compounds against MGMT protein, five phytochemicals were chosen based on their high docking scores and favorable binding energies. From the molecular docking and simulation studies, we found that quercetin showed a good inhibitory effect of MGMT with its high binding affinity. C6 glioma cells showed increased cytotoxicity when treated with the temozolomide and quercetin combination. It was understood from the isobologram and combination index plot that the drug combination showed a synergistic effect at the lowest dose. Quercetin when combined with temozolomide significantly decreased the MGMT levels in C6 cells in comparison with the other drugs as estimated by ELISA. The percentage of apoptotic cells increased significantly in the temozolomide–quercetin group indicating the potency of quercetin in decreasing the resistance of temozolomide as confirmed by acridine orange/ethidium bromide staining. Our experiment hence suggests that temozolomide resistance can be reduced by combining the drug with quercetin which will serve as an effective therapeutic target for glioblastoma treatment. | ||
| 650 | 4 | |a Glioblastoma |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Temozolomide |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a O |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a -methylguanine-DNA methyltransferase |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Phytochemical |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Resistance |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Rao, Vanishree |4 aut | |
| 700 | 1 | |a Cheruku, Sri Pragnya |4 aut | |
| 700 | 1 | |a Kumar, B. Harish |4 aut | |
| 700 | 1 | |a Maity, Swastika |4 aut | |
| 700 | 1 | |a Nandakumar, Krishnadas |4 aut | |
| 700 | 1 | |a Kumar, Lalit |4 aut | |
| 700 | 1 | |a Mehta, Chetan Hasmukh |4 aut | |
| 700 | 1 | |a Nayak, Usha |4 aut | |
| 700 | 1 | |a Chamallamudi, Mallikarjuna Rao |4 aut | |
| 700 | 1 | |a Kumar, Nitesh |0 (orcid)0000-0002-4929-3954 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t 3 Biotech |d Berlin : Springer, 2011 |g 13(2023), 12 vom: 02. Nov. |w (DE-627)SPR030851394 |w (DE-600)2600522-0 |x 2190-5738 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:12 |g day:02 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13205-023-03821-7 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 12 |b 02 |c 11 | ||